Acute Erythroleukemia in a Trauma Patient. A Case Report.
AJTES Vol 5, No 1, January 2021
PDF full text


acute erythroleukemia
myelodysplastic syndrome

How to Cite

Taulla, E. (2021). Acute Erythroleukemia in a Trauma Patient. A Case Report. Albanian Journal of Trauma and Emergency Surgery, 5(1), 819-821.


Introduction: Acute erythroid leukemia (AEL) is a rare type of acute myeloblastic leukemia. Acute erythroid leukemia is characterized by a predominant erythroid proliferation, there are 2 subtypes: erythroleukemia (erythroid/myeloid leukemia) and pure erythroid leukemia…

Myelodysplastic syndromes (MDS) are a group of biologically and clinically heterogeneous clonal disorders characterized by ineffective hematopoiesis and peripheral cytopenia due to high apoptosis

The purpose to presenting this case is how to differentiate an acute erythroleukemia (AEL) from myelodysplastic syndrome (MDS).

Case report. A 74-year-old man came to emergency room after he falling down from the stairs and then was hospitalized with a two weeks history of severe weakness, anorexia, weight loss. He suffered of diabetes mellitus type II insulin dependent, and HTA. The physical examination showed cutaneous and conjunctival pallor, large ecchymosis in the low extremities and hepatosplenomegaly. CBC showed: pancytopenia and macrocytosis, neutrophils 60%, normoblasts 4:100 and reticulocyte count 3%.

Conclusions: The diagnosis was Acute Erythroid Leukemia. The % of myeloblasts in bone marrow was > 20% of non-erythroid cells. Erythroleukemia characterizes from hepatomegaly this is found and in our case. Differential diagnosis is based mainly in bone marrow aspiration, immunophenotyping (flow cytometry).
PDF full text


1. Wintrobe’s Clinical Haematology 14th edition 76: pp 4935-5017
2. Oxford handbook of Clinical Haematology 4:120-131
3. Postgraduate Haematology 7th edition Clinical advances in Haematology and oncology. April 2010 vol.8 issue 4
5. Di Guglielmo G. Le Maltase Eritremiche Ed Eritroleucemiche. II Pensiero Scientifico. Haematologica. 1928; 9: 301-347.
6. Arber DA, Orazi A. Hasserjan R et al.the 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia Blood 2016 ;127 :2391-2405
7. Wei Wang, Sa A. Wang, L. Medeiros, Joseph D.Khoury American Journal of Haematology February 2017
8. Roggli VL, Saleem A. Erythroleukemia: a study of 15 cases and literature review. Cancer. 1982; 49: 101-108.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103: 620-625.
10. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (IARC WHO Classification of Tumours). 4th ed. Lyon, France: WHO Press; 2008.
11. Goldberg SL, Noel P, Lumpp TR, Dewald G. The erythroid leukemias: a comparative study of erythroleukemia (FABM6) and Di Guglielmo disease. Am J Clin Oncol. 1998; 21: 42-47.
12. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk directed therapy in acute myeloid leukemia derived from the MRC AML10 trial. Br J Haematol. 1999;107: 69-79.
13. Davey FR, Abraham N, Brunetto VL, et al. Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. Am J Hematol. 1995; 49: 29-38. 6 Clinical Advances in Hematology & Oncology Volume 8, Issue 4 April 2010
14. McHayleh W, Sehgal R, Redner RL, Raptis A, Agha M, Natale J, et al. Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin. Leuk Lymphoma. 2009 Oct 8. [Medline].
15. Stoneking CJ, Mason MJ. Mg2+ modulation of the single-channel properties of KCa3.1 in human erythroleukemia cells. Pflugers Arch. 2013 Nov 6. [Medline].
16. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6. 331(14):896-903. [Medline].
17. Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 Jan 15. 79(2):313-9. [Medline].
18. Kowal-Vern A, Mazzella FM, Cotelingam JD, et al. Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. Am J Hematol. 2000; 65: 5-13.
19. Olopade OI, Thangavelu M, Larson RA, et al. Clinical, morphologic and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992; 80: 2873-2882.
20. Mazzella F, Alvares C, Kowal-Vern A, Schumacher H. The acute erythroleukemias. Clin Lab Med. 2000; 20:119-137.
21. Kowal-Vern A, Cotelingam J, Schumacher HR. The prognostic significance of proerythroblasts in acute erythroleukemia. Am J Clin Pathol. 1992; 98: 34-40.
22. Southcott MJ, Tanner MJ, Anstee DJ. The expression of human blood group antigens during erythropoiesis in a cell culture system. Blood. 1999; 93: 4425-4435.
23. Garand R, Duchayne E, Blanchard D, et al. Minimally differentiated erythroleukemia (AML M6 ‘variant’): a rare subset of AML distinct from AML M6. Groupe Francais d Hematologie Cellulaire. Br J Haematol. 1995; 90: 868-875.
24. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues (WHO Classification of Tumours). Lyon, France: IARC Press; 2001.
25. Atkinson J, Hrisinko MA, Weil SC. Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature. Blood Rev. 1992; 6: 204-214.
26. Park S, Picard F, Azgui Z, et al. Erythroleukemia: a comparison between the previous FAB approach and the WHO classification. Leuk Res. 2002; 26: 423-429.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.